Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 10/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.76 |
| ▸ | MAPK7 | Q13164 | 11/20 | 0.74 |
| ▸ | BRD4 | O60885 | 2/20 | 0.71 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.71 |
| ▸ | DCLK2 | Q8N568 | 2/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.71 |
| ▸ | PI4KA | P42356 | 1/20 | 0.71 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.71 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.71 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.71 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.71 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.62 |
| ▸ | PIK3C2G | O75747 | 2/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797848 | 1.00 | DCLK1 (1.00) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL17721088 | 0.92 | DCLK1 (0.84) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL619501 | 0.89 | MAPK7 (0.83) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL22137421 | 0.89 | DCLK1 (0.80) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL10098748 | 0.89 | LRRK2 (0.79) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL17465883 | 0.88 | DCLK1 (0.78) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL10098761 | 0.87 | LRRK2 (1.00) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL17465886 | 0.87 | LRRK2 (0.77) | DCLK1LRRK2TNK2MAPK7BRD4 | |
| SCHEMBL16065780 | 0.86 | TNK2 (1.00) | DCLK1LRRK2TNK2MAPK7 | |
| SCHEMBL10098753 | 0.86 | PIK3CD (0.80) | DCLK1LRRK2TNK2MAPK7BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10793571-B2 | Uses of diazepane derivatives | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2015117083-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015117087-A1 | USES OF DIAZEPANE DERIVATIVES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2014145909-A2 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885TNK2 53/4885 |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | DCLK1 480/4885LRRK2 364/4885TNK2 85/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885TNK2 53/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | DCLK1 1082/4885LRRK2 1732/4885TNK2 352/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885TNK2 53/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885TNK2 53/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | DCLK1 453/4885LRRK2 340/4885TNK2 82/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | DCLK1 453/4885LRRK2 340/4885TNK2 82/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885TNK2 53/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885TNK2 53/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | DCLK1 1875/4885LRRK2 1955/4885TNK2 1560/4885 |
| US-10793571-B2 | Uses of diazepane derivatives | BRDT, BRD4, BRD3 | DCLK1 3728/4885LRRK2 1196/4885TNK2 1738/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | DCLK1 1082/4885LRRK2 1732/4885TNK2 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.